Navigation Links
Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement
Date:6/30/2009

LAKE FOREST, Ill., June 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced agreements with MedAssets on intravenous (I.V.) solutions and gravity I.V. equipment, and a renewal of its agreement for infusion devices. The five-year MedAssets agreements are effective as of June 1, 2009, for I.V. solutions and equipment, and July 1, 2009, for infusion devices. These new agreements represent a first for Hospira from a contract award position on I.V. solutions and gravity I.V. equipment.

"MedAssets shares Hospira's commitment to improving patient and healthcare safety, as well as finding ways to reduce the high costs of healthcare," said Pete Baker, vice president and general manager, Commercial Service Operations, Hospira. "We look forward to continuing our work with MedAssets' member healthcare institutions to drive these goals."

The agreements, all of which run through June 30, 2014, are multi-source awards. They include Hospira's general-purpose medication management technologies, such as the Plum A+(R) device; the next-generation Symbiq(R) infusion system with Hospira MedNet(R) safety software; and pain management pumps, such as the LifeCare PCA(R) device with Hospira MedNet(R) safety software, and GemStar(R) ambulatory devices. These products play a critical role in improving patient safety as well as enhancing quality of care and clinician workflow. Also covered within the agreements is access to contracts for Hospira's I.V. solutions, including the company's environmentally preferable VisIV(R) container, and the IV solutions' associated equipment portfolio.

"We are pleased to expand our relationship with Hospira," said Mark Miriani, president of MedAssets Supply Chain Systems. "Adding Hospira's full line of I.V. solutions and gravity I.V. equipment to our existing portfolio provides additional options for our members as part of our flexible, customer-driven approach to reducing supply expenses for our members."

About MedAssets

MedAssets (Nasdaq: MDAS) partners with healthcare providers to improve their financial strength by implementing spend management and revenue cycle solutions that help control cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency. MedAssets serves more than 125 health systems, 3,300 hospitals and 30,000 non-acute care healthcare providers. For more information, visit www.medassets.com.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hospira Receives Favorable Court Decision on Eloxatin(R)
2. Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies
3. Hospira Names Brian Meadows Supply Chain Chief
4. Hospira Supports Newly Introduced Biogenerics Legislation
5. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
6. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
7. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
8. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
9. Hospira Expands Board of Directors
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Biogenerics Will Save Billions, Says Hospira CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):